<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665856</url>
  </required_header>
  <id_info>
    <org_study_id>YO42373</org_study_id>
    <nct_id>NCT04665856</nct_id>
  </id_info>
  <brief_title>Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer</brief_title>
  <acronym>SKYSCRAPER-02C</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter study in China is to evaluate the safety and efficacy of&#xD;
      tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus&#xD;
      atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-Assessed Progression-Free Survival (PFS) in the Primary Population</measure>
    <time_frame>From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 46 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) in the Primary Population</measure>
    <time_frame>From randomization to death from any cause (up to approximately 46 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS in the Intent-To-Treat (ITT) Population</measure>
    <time_frame>From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in the ITT Population</measure>
    <time_frame>From randomization to death from any cause (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed Confirmed Objective Response Rate (ORR) in the Primary Population</measure>
    <time_frame>From randomization up to approximately 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed Confirmed ORR in the ITT Population</measure>
    <time_frame>From randomization up to approximately 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed Duration of Response (DOR) in the Primary Population</measure>
    <time_frame>From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed DOR in the ITT Population</measure>
    <time_frame>From the first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed PFS Rates at 6 Months and 12 Months in the Primary Population</measure>
    <time_frame>Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-Assessed PFS Rates at 6 Months and 12 Months in the ITT Population</measure>
    <time_frame>Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rates at 12 Months and 24 Months in the Primary Population</measure>
    <time_frame>Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rates at 12 Months and 24 Months in the ITT Population</measure>
    <time_frame>Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score in the Primary Population</measure>
    <time_frame>Up to approximately 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTCD Assessed Using EORTC QLQ-C30 Score in the ITT Population</measure>
    <time_frame>Up to approximately 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events, Determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Tiragolumab at Specified Timepoints</measure>
    <time_frame>Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at treatment discontinuation (TD) visit (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Atezolizumab at Specified Timepoints</measure>
    <time_frame>Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at TD visit (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab</measure>
    <time_frame>Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ADAs to Atezolizumab</measure>
    <time_frame>Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 46 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tiragolumab + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Tiragolumab + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <other_name>MTIG7192A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Placebo + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <arm_group_label>Tiragolumab + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.</description>
    <arm_group_label>Placebo + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <arm_group_label>Tiragolumab + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100 mg/m^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.</description>
    <arm_group_label>Placebo + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
    <arm_group_label>Tiragolumab + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab Matching Placebo</intervention_name>
    <description>Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Placebo + Atezolizumab + Carboplatin and Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Histologically or cytologically confirmed Extensive-Stage Small Cell Lung Cancer&#xD;
             (ES-SCLC) per the modified Veterans Administration Lung Study Group (VALG) staging&#xD;
             system&#xD;
&#xD;
          -  No prior systemic treatment for ES-SCLC&#xD;
&#xD;
          -  For participants who have received prior chemoradiotherapy for limited-stage SCLC must&#xD;
             have had treatment with curative intent and a treatment-free interval of at least 6&#xD;
             months between the last dose/cycle of chemotherapy, thoracic radiotherapy, or&#xD;
             chemoradiotherapy and the diagnosis of ES-SCLC&#xD;
&#xD;
          -  Measurable diseases as defined by RECIST v1.1&#xD;
&#xD;
          -  Submission of a pre-treatment tumor tissue sample&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Participants not receiving therapeutic anticoagulation with International Normalized&#xD;
             Ratio (INR) and Activated Clotting Time (aPTT) &lt;/= 1.5 x ULN&#xD;
&#xD;
          -  Participants receiving therapeutic anticoagulation: stable anticoagulant regimen&#xD;
&#xD;
          -  Negative Human Immunodeficiency Virus (HIV) test at screening&#xD;
&#xD;
          -  Negative hepatitis B surface antigen (HBsAg) test at screening&#xD;
&#xD;
          -  Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at&#xD;
             screening accompanied by either of the following: negative total hepatitis B core&#xD;
             antibody (HBcAb) and/or positive total HBcAb test followed by a negative hepatitis B&#xD;
             virus (HBV) DNA test&#xD;
&#xD;
          -  Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody&#xD;
             test followed by a negative HCV RNA test&#xD;
&#xD;
          -  Negative Epstein-Barr virus (EBV) viral capsid antigen (VCA) IgM test or negative EBV&#xD;
             polymerase chain reaction (PCR) test at screening&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception, and agreement to refrain from donating&#xD;
             eggs&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive methods, and agreement to refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or actively progressing central nervous system (CNS) metastases&#xD;
&#xD;
          -  Spinal cord compression&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Known clinically significant liver disease, including active viral, alcoholic, or&#xD;
             other hepatitis, cirrhosis, and inherited liver disease, or current alcohol abuse&#xD;
&#xD;
          -  Malignancies other than SCLC within 5 years prior to randomization&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiencies&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest Computer Tomography (CT) scan&#xD;
&#xD;
          -  Known active tuberculosis, Current treatment with anti-viral therapy for HBV or HCV&#xD;
&#xD;
          -  Severe chronic or active infection&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Major surgical procedure other than for diagnosis&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplantation or solid organ transplant&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine&#xD;
&#xD;
          -  Prior treatment with CD137 agonists, T-cell co-stimulating, or immune checkpoint&#xD;
             blockade therapies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications&#xD;
&#xD;
          -  History of severe allergic anaphylactic reactions to chimeric or humanized antibodies&#xD;
             or fusion proteins&#xD;
&#xD;
          -  Known hypersensitivity to Chinese Hamster Ovary (CHO) cell products or to any&#xD;
             component of the tiragolumab or atezolizumab formulations&#xD;
&#xD;
          -  History of allergic reactions to carboplatin or etoposide&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment&#xD;
             or within 5 months after the final dose of atezolizumab or within 90 days after the&#xD;
             final dose of tiragolumab or for 6 months after the final dose of carboplatin or&#xD;
             etoposide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital; Oncology Department</name>
      <address>
        <city>Beijing</city>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu City</city>
        <zip>233000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou City</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department</name>
      <address>
        <city>Hangzhou City</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital of Nanchang Unversity</name>
      <address>
        <city>Nanchang City</city>
        <zip>330200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai City</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan City</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

